What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?


KESKİN Y. , Koz G., Nas K.

EURASIAN JOURNAL OF MEDICINE, vol.53, no.2, pp.132-136, 2021 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 53 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.5152/eurasianjmed.2021.20222
  • Title of Journal : EURASIAN JOURNAL OF MEDICINE
  • Page Numbers: pp.132-136
  • Keywords: Psoriatic Arthritis, COVID-19, SARS-CoV-2 Virus, Treatment, RHEUMATOID-ARTHRITIS

Abstract

Coronavirus disease 2019 is a respiratory infection caused by severe acute respiratory syndrome coronavirus 2. Coronavirus disease 2019 leads to the rapid activation of innate immune cells, particularly in patients with severe disease. Psoriatic arthritis is a heterogeneous chronic inflammatory disease characterized by the association of psoriasis and arthritis. Similar to those with other viruses, patients with psoriatic arthritis are at a significant risk of infection with severe acute respiratory syndrome coronavirus 2. Patients with psoriatic arthritis are immunosuppressed owing to immune dysregulation during the active disease period or owing to immunosuppressive drugs administered during remission, and they are prone to infections. The severe acute respiratory syndrome coronavirus 2 is a threat to millions of people globally owing to the decline in immunity and because a significant number of people develop severe illness. In the period of coronavirus disease 2019 pandemic, we briefly present recommendations for the treatment of psoriatic arthritis. In this review, we briefly address the management options and treatment recommendations for patients with psoriatic arthritis during and after the coronavirus disease 2019 pandemic in light of recent scientific publications.